Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.27 AUD | 0.00% | +8.00% | +12.50% |
Mar. 15 | Nova Eye Medical Completes Retail Entitlement Offer | MT |
Feb. 22 | Nova Eye Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.50% | 40.08M | - | ||
+7.71% | 220B | B | ||
+6.25% | 185B | B- | ||
+10.60% | 133B | B- | ||
+26.73% | 107B | A- | ||
-0.57% | 62.91B | A- | ||
+15.42% | 53.34B | B+ | ||
-1.89% | 47.71B | B+ | ||
-1.91% | 40.29B | A | ||
+11.16% | 39.57B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EYE Stock
- Ratings Nova Eye Medical Limited